食品科学 ›› 2026, Vol. 47 ›› Issue (3): 148-160.doi: 10.7506/spkx1002-6630-20250823-168

• 营养卫生 • 上一篇    下一篇

DIA蛋白质组学研究羧甲基茯苓多糖CMP33的抗糖尿病作用机理

陈金,管晶晶,黄柳芳,黄丽珊,曾晓敏,谭子悦,徐晓飞   

  1. (广东海洋大学食品科学与工程学院,广东 阳江 529500)
  • 出版日期:2026-02-01 发布日期:2026-03-16
  • 基金资助:
    广东省重点领域研发计划项目(2021B0707060001);广东海洋大学科研启动经费项目(360302062207); 广东省大学生创新创业训练计划资助项目(S202510566081)

Data-independent Acquisition-based Proteomic Analysis of the Anti-diabetic Mechanism of a Carboxymethylpachymaran from Poria coco (CMP33) on Mice

CHEN Jin, GUAN Jingjing, HUANG Liufang, HUANG Lishan, ZENG Xiaomin, TAN Ziyue, XU Xiaofei   

  1. (College of Food Science and Engineering, Guangdong Ocean University, Yangjiang 529500, China)
  • Online:2026-02-01 Published:2026-03-16

摘要: 为探究β-(1,3)-葡聚糖的抗糖尿病作用及其生物学机理,采用羧甲基茯苓多糖CMP33灌胃高脂饲料(high-fat-diet,HFD)联合链脲佐菌素(streptozotocin,STZ)处理的小鼠模型,同时设立正常组、模型组和二甲双胍对照组,检测体质量、脏器指数、血液糖脂代谢指标、炎症因子指标和肝脏氧化应激指标的变化,并采用基于数据非依赖采集(data-independent acquisition,DIA)的蛋白质组学技术分析模型组和CMP33组小鼠肝脏蛋白质组。结果表明,HFD/STZ成功构建了糖尿病模型,CMP33缓解了糖尿病小鼠体质量下降,改善了肝脏和胰腺损伤,有效降低了血糖、糖耐量、糖化血红蛋白和甘油三酯水平,提高了胰岛素水平,表现出良好的抗糖尿病作用。DIA肝脏蛋白质组学检测鉴定出255 个差异表达蛋白(differential expressed proteins,DEPs),其中上调134 个,下调121 个。生物学信息分析显示这些DEPs主要介导了脂质代谢与调控、核苷酸分解代谢、自噬、胰岛素信号和葡萄糖转运等生物过程,并富集到疾病(癌症、代谢性疾病和神经退行性疾病)、代谢调节和信号传导等京都基因与基因组百科全书通路,说明CMP33对糖尿病小鼠的改善作用具有多靶点、多途径和协同作用的特点。蛋白互作分析显示GTP酶HRas、组蛋白赖氨酸N-甲基转移酶2D、泛素样负调节因子1、组蛋白H2A、长链脂肪酸转运蛋白1、ATP柠檬酸合成酶和乙酰辅酶A合成酶可能是肝脏中响应CMP33作用的关键蛋白。这些结果证明了β-(1,3)-葡聚糖的抗糖尿病作用,并从蛋白质表达角度提供了β-(1,3)-葡聚糖抗糖尿病的生物学机理见解,拓展了对多糖抗糖尿病机理的认知,为β-(1,3)-葡聚糖在糖尿病管理功能食品中应用提供了科学理论依据。

关键词: β-(1,3)-葡聚糖;糖代谢;脂代谢;蛋白质组学;差异表达蛋白

Abstract: To investigate the anti-diabetic effect of β-(1,3)-glucan and the underlying biological mechanism, a diabetic mouse model was established by high-fat-diet (HFD) feeding combined with streptozotocin (STZ) injection. Four groups of mice were set up: a normal, model, and metformin-treated, and CMP33 (a carboxymethylpachymaran from Poria coco)-treated group. Changes in body mass, organ indices, blood glucose and lipid metabolism indicators, inflammatory indicators, and hepatic oxidative stress indicators were measured. Additionally, proteomic analysis of the liver of mice in the model and CMP33 groups was performed using data-independent acquisition (DIA). The results showed that CMP33 alleviated body mass loss, mitigated liver and pancreas damage, effectively reduced blood glucose, glucose tolerance, glycated hemoglobin, and triglyceride levels, and increased insulin levels in diabetic mice, exhibiting potent anti-diabetic effect. DIA-based proteomics identified 255 differentially expressed proteins (DEPs), including 134 upregulated and 121 downregulated proteins. Bioinformatic analysis revealed that these DEPs primarily participated in biological process such as lipid metabolism regulation, nucleotide catabolism, autophagy, insulin signaling, and glucose transport and were primarily enriched in Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways related to diseases (such as cancer, metabolic diseases, and neurodegenerative diseases), metabolic regulation, and signal transduction pathways, underscoring that CMP33 protected against diabetes through a multi-target and multi-pathway mechanism. Protein-protein interaction analysis highlighted that GTPase HRas, histone-lysine N-methyltransferase 2D, NEDD8 ultimate buster 1, histone H2A type 1, long-chain fatty acid transport protein 1, ATP-citrate synthase, and acetyl-coenzyme A synthetase might be the key proteins responsive to CMP33. These results demonstrate the anti-diabetic effect of β-(1,3)-glucan and provide insights into the underlying biological mechanism from a proteome perspective. The findings expand our understanding of the mechanisms by which polysaccharides exert anti-diabetic effects and offer a scientific basis for the application of β-(1,3)-glucan in functional foods for diabetes management.

Key words: β-(1,3)-glucan; glucose metabolism; lipid metabolism; proteomics; differentially expressed proteins

中图分类号: